Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations

Stock Track

06/11

Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.

The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.

The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1139874515"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139874515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139874515?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139874515","market":"hk","top_or_hot":-1,"title":"Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations","media":"Stock Track","content":"<p>Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.</p><p>The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.</p><p>The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-06-11 00:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.</p><p>The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.</p><p>The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PBLS","symbol_name":"Parabilis Medicines","start_time":0,"source_url":"","article_id":"1139874515","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139874515","pubTimestamp":1781110004,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.The significant surge is attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PBLS":"Parabilis Medicines"},"translate_title":"个股追踪|Parabilis Medicines盘中大涨66.75%成功IPO定价超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBLS":1},"content_text":"Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}